Ξεχάσατε τον κωδικό σας;
Keywords
- ABPA_Aspergillus
- accompanying diseases
- air-improving devices
- allergy
- animals_pets
- antibiotic therapy
- asthma
- complementary medicine
- covid-19
- diabetes
- diagnostics
- drugs side effects
- drugs under development_genetic therapy
- ENT
- general aspects
- genetics
- health care
- hepatobiliary disease
- hygiene
- i.v.-lines
- inhalation
- lung
- microbiology
- miscellaneous
- modulator therapy
- MRSA
- nutrition and GI problems
- oxygen supplementation_therapy
- physiotherapy
- Pseudomonas aeruginosa
- psychosocial
- public facilities
- recreational activities
- reproduction
- research
- social law
- sport
- swine flu_novel influenza
- transplantation
- travelling
- vaccination
- ventilation
Topics
- Combination therapy: Kalydeco+VX809
- Following recent results presented at the NACFC in Orlando, it seems that the association Kalydeco+VX809 is promising. Will the drug be commercially available in 2015/2016?
- 12.11.2012
- Genetics IVS8T5 - Delta F 508
- Which treatment options exist for this specific genetic situation? And can one reckon with the development of specific drugs? Kind regards.
- 29.10.2012
- ataluren
- Hello Do you have information about the next steps in the ataluren development? When will the open study be completed ? And when will we have the results? Thank you for your site
- 25.10.2012
- Ataluren with stop mutation R1162X
- Unfortunately the latest results that were published at the CF congress in Dublin are not really convincing. I have the following question nevertheless: Is it true that the R1162X stop mutation is suited very well or at least better than other stop mutations for therapy with Ataluren? Were ...
- 11.09.2012
- Why are Ataluren results considered disappointing?
- [In this Q/A two questions were summerized as the given answer was the same, both questions can be read here] Hello, I read about the phase-III study on Ataluren as well as the PTC press release on the website of the German CF patient association, and I do not really understand why the ...
- 11.09.2012
- Vertex® agent for 18 patients realistic?
- Dear expert team, For some time now, I have been following Vertex® (via their website), who have successfully completed clinical trials for a mutation-based therapy for ca. 4% of CF patients with KalydecoTM. KalydecoTM was now approved in Europe as well on July 27. I am happy for the 1500 ...
- 13.08.2012
- CF with F508del and G542X mutations
- Hello, My son was born in april 2011. He was diagnosed with CF (two mutations G542X and F508del). Are there any progress on treatments that could cure these two mutations? He never had any diseases, it receives his Physio and takes Creon, the ADEK vitamins and does not gain much weight. Yours
- 13.08.2012
- Ataluren
- When will Ataluren be available in Germany?
- 02.08.2012
- Ataluren
- Does Ataluren help with the Delta F508 mutation?
- 02.08.2012
- MIGLUSTAT
- Hello, The latest results of Miglustat's clinical trials were not those expected. Are researches on this molecule definitively abandoned? Thank you in advance for your response
- 30.07.2012